ClinicalTrials.gg
CompletedNCT04225208Updated Aug 24, 2020

Pharmacokinetic and Mass Balance Study of Orally Administered [14C]-AZD4205 in Healthy Adult Male Volunteers

A Phase 1 interventional study of [14C]-AZD4205, single 50 mg oral dose administrated on day 1 in Healthy Volunteers, sponsored by Dizal Pharmaceuticals. Completed at 1 site in United States. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-08-24.

Sponsored by Dizal Pharmaceuticals · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Mar 2020, 6 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
Male
01

Study summary

This is a phase I, open label, healthy volunteers, ADME study with single oral administration of [14C]-AZD4205.

Read the detailed description

Phase I study to evaluate the excretion of AZD4205 radioactive dose, the metabolic profile, pharmacokinetics, safety and tolerability following a single oral administration of [14C]-AZD4205 in healthy male volunteers. The purpose of this study is to investigate ADME properties of AZD4205 by analyzing blood, urine and feces collected during the study

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Dizal Pharmaceuticals is the lead sponsor of 39 studies on the registry; 15 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 1 (7%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Healthy male subjects aged 18 to 65, who must be willing to use reliable methods of , even if their partners are , surgically sterile, or using an effective hormonal method of contraception or intrauterine coil.
    1. In addition, subjects must agree to continue to take similar contraceptive precautions until 6 months after administration of AZD4205 and avoid procreative sex as well as sperm donation for 6 months after administration of AZD4205.

Exclusion criteria

Exclusion Criteria:

    1. Any abnormalities in physical examination, vital signs, hematology, clinical chemistry, urinalysis or at screening or baseline in the opinion of the investigator.
    1. Subjects who may have been exposed to radiation for therapeutic or diagnostic reasons at levels above background (e.g,, through X-ray examination other than dental X-rays or plain X-rays of thorax or bony skeleton) of > 5 mSv in last year, > 10 mSv over last 5 years or a cumulative total of > 1 mSv per year of life.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    [14C]-AZD4205

    A single dose of \[14C\]-AZD4205

    Drug: [14C]-AZD4205, single 50 mg oral dose administrated on day 1

Interventions

  • Drug[14C]-AZD4205, single 50 mg oral dose administrated on day 1

    Drug page: Golidocitinib

    Each subject will receive 50 mg AZD4205 oral solution (free base equivalent) containing a nominal dose of 15 µCi \[14C\]- radiolabelled AZD4205 as a single administration .

06

What researchers measure

Primary outcomes

  1. Percentage of radioactive dose recovered in urine and faeces and total percentage

    To evaluate the percentage of radioactive dose of \[14C\] radiolabelled AZD4205 recovered in urine, feces, and in total

    Time frame: Up to 57 days

  2. Provide samples for subsequent studies

    Provide samples for subsequent studies to characterize the metabolism of \[14C\]AZD4205

    Time frame: Up to 57 days

Secondary outcomes

  1. AUC(0-inf) for [14C] radioactivity in plasma and whole blood

    To determine AZD4205 plasma concentrations and the resulting AUC(0-inf)

    Time frame: Up to 57 days

  2. AUC(0-t) for [14C] radioactivity in plasma and whole blood

    To determine AZD4205 plasma concentrations and the resulting AUC(0-t)

    Time frame: Up to 57 days

  3. Cmax for [14C] radioactivity in plasma and whole blood

    To determine AZD4205 plasma concentrations and the resulting Cmax

    Time frame: Up to 57 days

  4. tmax for [14C] radioactivity in plasma and whole blood

    To determine AZD4205 plasma concentrations and the resulting tmax

    Time frame: Up to 57 days

  5. tlag for [14C] radioactivity in plasma and whole blood

    To determine AZD4205 plasma concentrations and the resulting tlag

    Time frame: Up to 57 days

  6. t1/2 for [14C] radioactivity in plasma and whole blood

    To determine AZD4205 plasma concentrations and the resulting t1/2

    Time frame: Up to 57 days

  7. λz for [14C] radioactivity in plasma and whole blood

    To determine AZD4205 plasma concentrations and the resulting λz

    Time frame: Up to 57 days

  8. CL/F for [14C] radioactivity in plasma and whole blood

    To determine AZD4205 plasma concentrations and the resulting CL/F

    Time frame: Up to 57 days

  9. Vss/F for [14C] radioactivity in plasma and whole blood

    To determine AZD4205 plasma concentrations and the resulting Vss/F

    Time frame: Up to 57 days

  10. Distribution of total radioactivity in blood

    To compare disposition of drug-related total radioactivity in whole blood to that in plasma

    Time frame: Up to 57 days

Other outcomes

  1. Number of participants with treatment-related adverse events, and serious adverse events

    To assess the safety and tolerability of a single dose of AZD4205 in healthy adult male subjects.

    Time frame: Up to 57 days

07

Study locations

1 site
  • Pharmaron CPC
    Baltimore, Maryland 21201, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2020 to primary completion in Mar 2020, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2020
First posted
Jan 13, 2020
StartActual
Jan 6, 2020
Primary completionActual
Mar 2, 2020
CompletionActual
Mar 2, 2020
Last update
Aug 24, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04225208
Responsible party
Sponsor
First posted
Jan 13, 2020
Start date
Jan 6, 2020
Primary completion
Mar 2, 2020
Completion
Mar 2, 2020
Last update
Aug 24, 2020

Study contacts

Royce Morrison
principal investigator · Pharmaron CPC

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Golidocitinib

Start the discussion